Clinical trials: High-Risk Cancer
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for…
- Trial name
- NCT04264806
- Testing
- Azacitidine, Cusatuzumab
- Where
- 73 sites in Australia, Brazil and 9 more
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer
A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA
(Neo)adjuvant treatment approaches and outcomes
- Trial name
- ERA (NCT05939128)
- Where
- 19 sites in Russia
- Volunteers
- 625 people
- Sponsor
- AstraZeneca
Osteosarcoma
Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.
An open-label, multicenter, phase I/II clinical trial to identify the [6R] 5,10-methylenetetrahydrofolate (arfolitixorin) dose with most favorable safety prospect and confirmed ability to mitigate high-dose methotrexate induced…
- Trial name
- NCT01987102
- Testing
- Calcium Folinate, [6R] 5,10-methylenetetrahydrofolate (arfolitixorin)
- Where
- 5 sites in Czechia, Hungary and 2 more
- Volunteers
- 18 people
- Sponsor
- Isofol Medical AB
Glioblastoma Multiforme
Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM
This is a prospective, open-label, single arm, historical control pilot study aimed to test the effectiveness and safety of TTFields delivered through high intensity arrays in recurrent glioblastoma.
- Trial name
- NCT04492163
- Testing
- TTFields
- Where
- Czechia
- Volunteers
- 25 people
- Sponsor
- NovoCure GmbH
Papilloma Viral Infection, CIN1
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
HPV infection can lead to cancer, especially when precancerous lesions have developed and high-risk HPV is present. Glizigen is an oral and intravaginal treatment based on activated glycyrrhizinic acid that has shown potential…
- Conditions
- Papilloma Viral Infection, CIN1, LSIL, Low Grade Squamous Intraepithelial Lesion
- Trial name
- NCT05916911
- Testing
- Glizigen
- Where
- 4 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Catalysis SL
Prostatic Neoplasms
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
The purpose of this registry study is to longitudinally observe clinical outcomes and patient-reported outcomes (PRO) for participants with high-risk metastatic hormone-naive prostate cancer (mHNPC) in the real-world setting in…
- Trial name
- NCT04034095
- Testing
- Androgen-deprivation Therapy (ADT), Bicalutamide, Abiraterone
- Where
- 77 sites in Japan
- Volunteers
- 979 people
- Sponsor
- Janssen Pharmaceutical K.K.
Bladder Cancer
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
This Phase Ib/II study is designed to assess the safety, tolerability, pharmacokinetics, immunogenicity, patient reported outcomes (PROs), and preliminary anti-tumor activity of atezolizumab administered by intravenous (IV)…
- Trial name
- NCT02792192
- Testing
- Atezolizumab, Bacille Calmette-Guérin
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Esophageal Neoplasms
KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
The goal of this observational study is to test the clinical efficacy of "KCNA3 and OTOP2 gene methylation combined detection kit (fluorescence PCR method)"in esophageal cancer and high-grade esophageal neoplasia auxiliary…
- Trial name
- NCT05680077
- Testing
- KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
- Where
- China
- Volunteers
- 1,116 people
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Breast Fibroadenoma
Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)
This is a multi-center, crossover study with cluster randomization and a planned accrual of 300 patients with diagnosed breast fibroadenoma (One fibroadenoma treated per patient).
- Trial name
- NCT03742401
- Testing
- Surgery, HIFU (Echopulse)
- Where
- 12 sites in France
- Volunteers
- 2 people
- Sponsor
- Theraclion
Epithelial Ovarian Cancer
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or…
- Trial name
- TREVI-OC-01 (NCT07218809)
- Testing
- AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel
- Where
- 299 sites in United States, Australia and 22 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 66 sites in United States, China and 1 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Metastatic Castration-Resistant Prostate Cancer Patients
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
The study seek to evaluate the anti-tumor effect after treatment of Irofulven in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic…
- Trial name
- NCT03643107
- Testing
- Irofulven, Prednisolone 10 mg
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Allarity Therapeutics
Various Advanced Cancer
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
- Trial name
- CheckMate 274 (NCT02632409)
- Testing
- Nivolumab
- Where
- 188 sites in United States, Argentina and 28 more
- Volunteers
- 709 people
- Sponsor
- Bristol-Myers Squibb
Chemotherapy-Induced Neutropenia, Breast Cancer
Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy
This is an investigation of the safety and efficacy of Maxy-G34 in breast cancer patients treated with TAC chemotherapy. Maxy-G34 will be given as a single injection during each cycle of chemotherapy, for a planned total of six…
- Trial name
- NCT00501332
- Testing
- Maxy-G34
- Where
- 15 sites in Poland, Romania and 2 more
- Volunteers
- 30 people
- Sponsor
- Maxygen Holdings Ltd.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum…
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer
- Trial name
- NCT05483933
- Testing
- Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 86 people
- Sponsor
- Shattuck Labs, Inc.
Prostatic Neoplasms, Prostate Cancer
Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer
This trial uses a ultra high-resolution ultrasound system and specialized transducer, intended for use in prostate imaging. The system's image resolution is significantly better than the standard of care, due to its higher…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT02079025
- Testing
- High-resolution ultrasound guided prostate biopsy, Standard ultrasound guided prostate biopsy
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,676 people
- Sponsor
- Exact Imaging
Non-Hodgkin's Lymphoma, Lymphoma, Diffuse
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
This study is being done to assess the safety and tolerance of different doses of humanized hA20 in patients with NHL.
- Conditions
- Non-Hodgkin's Lymphoma, Lymphoma, Diffuse, Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic
- Trial name
- NCT00596804
- Testing
- veltuzumab
- Where
- 3 sites in France, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated…
- Conditions
- B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma
- Trial name
- STARLIGHT-1 (NCT06343311)
- Testing
- EB103
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Estrella Immunopharma, Inc.
Advanced Solid Tumor Cancer
A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors
This is an open-label, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of YF087 in subjects with Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) advanced solid…
- Trial name
- NCT07809607
- Testing
- YF087
- Volunteers
- 70 people
- Sponsor
- InventisBio Co., Ltd
AML and High Risk MDS
A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
This study will assess the safety and preliminary efficacy of escalating doses of LGH447 monotherapy in AML and MDS and LGH447 in combination with midostaurin in AML.
- Trial name
- NCT02078609
- Testing
- LGH447, LGH447 + midostaurin
- Where
- 9 sites in United States, Australia and 5 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.